drugset / Trial / NCT01380691

A Study of LY2216684 in Healthy Participants

NCT01380691

Phase 1 Completed 28 enrolled Eli Lilly and Company
RandomizedCrossoverDouble-blindTreatment

Summary

This study will evaluate the pharmacodynamic and pharmacokinetic interaction of LY2216684 with alcohol in healthy participants. This study will run approximately for 34 days.

Timeline

Start
2011-06
Primary completion
2011-09
Completion
2011-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Alcoholic beverage Unknown 0.6 g/kg Oral
Subject Alcoholic beverage Unknown 0.7 g/kg Oral
Subject edivoxetine Small molecule 18 mg Oral